WGS

Exciting BioAro and MyCare Partnership Advances Serious Disease Detection

Retrieved on: 
星期四, 二月 8, 2024
AB, Health equity, Partnership, Life, Health, Whole genome sequencing, WGS, DNA, Genome, International, Gene, Marker beacon, Longevity, Biomarker, Nursing

These highly confidential tests allow individuals to embark on a revolutionary genetic journey to unveil a person's complete DNA sequence.

Key Points: 
  • These highly confidential tests allow individuals to embark on a revolutionary genetic journey to unveil a person's complete DNA sequence.
  • Their advanced technology decodes every chromosome, revealing crucial biomarkers for serious diseases, longevity and healthspan.
  • Our goal is to empower individuals to be the CEO of their health," says Raman Kapoor, B.Sc, RD, Chief Healthspan Officer, BioAro.
  • BioAro handles all order processing, performs the test and responds with detailed test results and recommendations based on test outcomes.

Twist Bioscience Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications

Retrieved on: 
星期二, 二月 6, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Whole genome sequencing, Liquid biopsy, Twist Bioscience, Workflow, DNA, Circulating tumor DNA, Patient, Doctor of Philosophy, Disease, Silicon, Neoplasm, NGS, Twist, WGS, Cancer, MRD, Nucleic acid thermodynamics

The Twist cfDNA Library Preparation Kit was purpose-built to maximize the number of unique cfDNA molecules that are captured in library preparation, for higher confidence in the accuracy and sensitivity of liquid biopsy tests.

Key Points: 
  • The Twist cfDNA Library Preparation Kit was purpose-built to maximize the number of unique cfDNA molecules that are captured in library preparation, for higher confidence in the accuracy and sensitivity of liquid biopsy tests.
  • With exceptional accuracy and sensitivity enabled by high conversion rates, the Twist cfDNA Library Preparation Kit can help push the limit of detection and detect lower frequency variants that can be missed by other on market library preparation solutions.”
    The Twist cfDNA Library Preparation Kit adds to Twist’s growing portfolio of tools to support the research and development of liquid biopsy assays, which also includes the recently launched Twist cfDNA Pan-Cancer Reference Standard v2 .
  • The Twist cfDNA Library Preparation Kit can address challenges associated with library preparation from circulating cfDNA with reliable and robust performance from as little as 1ng sample input.
  • The Twist cfDNA Library Preparation Kits are available in two configurations: the cfDNA Library Preparation Kit for whole genome sequencing (WGS) workflows and the Twist Library Preparation and Hyb Mix Kit for target enrichment.

Parkinson's Foundation to Accelerate Research Through Expanded Genetic Testing and Counseling Study

Retrieved on: 
星期二, 二月 6, 2024
Partnership, Ageing, Knowledge, ASAP, Parkinson's disease, Research, NIH, Genetics, Gene, Columbia University, Genetic testing, Physician, Parkinson's Foundation, Disease, Science, Genetic counseling, Genetic, National Institute on Aging, Bangladesh Technical Education Board, Doctor of Philosophy, WGS, PD, Pharmaceutical industry

NEW YORK and MIAMI, Feb. 6, 2024 /PRNewswire/ -- Through its Global Parkinson's Genetics Program (GP2), Aligning Science Across Parkinson's (ASAP) has awarded the Parkinson's Foundation a grant that will significantly expand its landmark international genetics study, PD GENEration: Mapping the Future of Parkinson's Disease. The study provides genetic testing and genetic counseling to people with Parkinson's disease (PD). ASAP's funding will allow the Foundation to accelerate the study's impact by focusing on those who have been historically underrepresented in research.

Key Points: 
  • The study provides genetic testing and genetic counseling to people with Parkinson's disease (PD).
  • ASAP's funding will allow the Foundation to accelerate the study's impact by focusing on those who have been historically underrepresented in research.
  • It is a patient-facing research study," said Parkinson's Foundation Senior Vice President and Chief Scientific Officer James Beck, PhD.
  • Fox Foundation for Parkinson's Research is ASAP's implementation partner and issued the grants on behalf of ASAP and GP2.

Twist Bioscience Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT

Retrieved on: 
星期一, 二月 5, 2024
Health, Technology, Genetics, Agritech, Research, Science, Biotechnology, Whole genome sequencing, Twist Bioscience, Workflow, Library, NBL, UHT, Kit, Chemistry, Automation, Doctor of Philosophy, UDI, Genomics, Silicon, NGS, Twist, Breeding, WGS, Fine chemical

Built upon enzymatic fragmentation library preparation, the Twist Flex Prep UHT Kit utilizes novel chemistry that accepts and self-normalizes a wide range of sample input amounts through a new proprietary Normalization By Ligation (NBL) technology.

Key Points: 
  • Built upon enzymatic fragmentation library preparation, the Twist Flex Prep UHT Kit utilizes novel chemistry that accepts and self-normalizes a wide range of sample input amounts through a new proprietary Normalization By Ligation (NBL) technology.
  • The enhanced multiplexing further limits hands on time and saves researchers costs of reagents in downstream purification and indexing steps.
  • Twist will highlight its NGS tools in posters and presentations at the AGBT General Meeting taking place in Orlando, FL February 5-8, 2024.
  • Details are as follows:
    Poster: Twist Pan-Cancer Reference Standards V2: Enhanced Precision and Reduced Errors in ctDNA Analysis

MGI Enters Strategic Partnership with Prepaire Labs to Advance Drug Discovery and Precision Medicine

Retrieved on: 
星期一, 二月 5, 2024
Partnership, Whole genome sequencing, Co-marketing, Dubai World Trade Centre, T20, Drug discovery, WGBS, MGI, Medicine, Genomics, WGS, Genome, Antibiotics

"This partnership is a testament to our commitment to expand global access to genomics through cutting-edge and high-quality platforms."

Key Points: 
  • "This partnership is a testament to our commitment to expand global access to genomics through cutting-edge and high-quality platforms."
  • MGI and Prepaire Labs will focus on:
    Developing assays for whole genome sequencing.
  • Founded in 2020, Prepaire Labs is an Abu Dhabi-based company focused on revolutionizing drug discovery and precision medicine.
  • Carl Freer, founder of Prepaire Labs, commented, "Our collaboration with MGI is a testament to our mission of bringing advanced genomic sequencing closer to clinical applications.

GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024 

Retrieved on: 
星期四, 二月 1, 2024
WGS, GeneDx

STAMFORD, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the fourth quarter of 2023 after the market closes on Tuesday, February 20, 2024.

Key Points: 
  • STAMFORD, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the fourth quarter of 2023 after the market closes on Tuesday, February 20, 2024.
  • Management will host a conference call that day to discuss 2023 financial and operating results and share full year 2024 guidance at 4:30 p.m. Eastern Time.
  • Investors interested in listening to the conference call are required to register online.
  • A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/ .

ProPhase Labs Ushers in New Genomics Era with Jason Karkus at the Helm of Nebula Genomics

Retrieved on: 
星期二, 一月 30, 2024
Prophase, Growth, Whole genome sequencing, Therapy, Karkus, Nebula Genomics, Marketing, Genomics, Acquisition, Health, Nebula, WGS

Garden City, NY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jason Karkus, one of the driving forces behind ProPhase Diagnostics, becomes President of Nebula Genomics, a wholly-owned subsidiary of ProPhase Labs.

Key Points: 
  • Garden City, NY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jason Karkus, one of the driving forces behind ProPhase Diagnostics, becomes President of Nebula Genomics, a wholly-owned subsidiary of ProPhase Labs.
  • This fiscal achievement fueled ProPhase's growth and strategic acquisition of Nebula Genomics.
  • In his new role, Karkus aims to amplify the Nebula Genomics business-to-business operations, as well as its exciting direct-to-consumer Whole Genome Sequencing (WGS) model.
  • As ProPhase focuses on its WGS business lines, Karkus’ leadership, energy and vision are expected to be a driving force.

Baylor Genetics Chief Medical Officer Christine Eng, M.D., Shares Sequencing Approaches for Undiagnosed Patients at Precision Medicine World Conference 2024

Retrieved on: 
星期二, 一月 23, 2024
Silicon, Whole genome sequencing, M.D, Patient, DSM-IV codes, Harvard University, Intensive care medicine, NICU, Baylor College of Medicine, Gene, WGS, Blog, Genetics, WES, Genetic testing, PICU, Conference, NIH, Sequence, Genome, Clinical trial, Bangladesh Technical Education Board, Hall, Diagnosis, UDN

Eng’s presentation will focus on the groundbreaking work and clinical findings from the National Institutes of Health’s (NIH) Undiagnosed Diseases Network (UDN).

Key Points: 
  • Eng’s presentation will focus on the groundbreaking work and clinical findings from the National Institutes of Health’s (NIH) Undiagnosed Diseases Network (UDN).
  • Baylor Genetics and partner Baylor College of Medicine have served as the sole sequencing core for UDN since its inception in 2014, providing WGS/WES testing, interpretation, validation and reporting for patients with rare genetic diseases.
  • The Harvard Gazette recently published one such story, noted in a Baylor Genetics blog on navigating the maze of undiagnosed diseases.
  • Learn more about PMWC through the conference website and visit the Baylor Genetics website to explore the company’s full spectrum of genetic testing capabilities.

Gattaca Genomics Unveils State-of-the-Art Genetic Testing Services to Transform Family Planning

Retrieved on: 
星期四, 一月 18, 2024
Entrepreneurship, Family, Whole genome sequencing, Patient, Regenerative medicine, Heart, IVF, Knowledge, Reproductive medicine, Genetics, WGS, Genetic testing, Risk, Quality of life, Genomics, Genetic counseling, Genome, DSM-IV codes, PGT, Chromosome, Management

Fort Lauderdale, FL, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics, a pioneering next generation company innovating solutions for reproductive health, is set to revolutionize family planning with its advanced genetic testing services.

Key Points: 
  • Fort Lauderdale, FL, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics, a pioneering next generation company innovating solutions for reproductive health, is set to revolutionize family planning with its advanced genetic testing services.
  • Specializing in Preimplantation Genetic Testing (PGT), Gattaca Genomics employs state-of-the-art techniques to enhance pregnancy success rates, identify chromosomal abnormalities, and reduce the risk of genetic disorders.
  • Whole Genome Sequencing (WGS): Gattaca Genomics introduces a breakthrough in genetic testing with Whole Genome Sequencing, offering a comprehensive analysis of an individual's entire genome.
  • Gattaca Genomics invites prospective parents, healthcare providers, and clinicians to explore the possibilities that genetic testing can offer.

GeneDx Announces Preliminary 2023 Financial Results

Retrieved on: 
星期一, 一月 8, 2024
Annual report, Risk, Exome, Growth, Eye, Bank statement, Legacy, Genome, Intelligence, WGS, GeneDx, Video game

STAMFORD, Conn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported preliminary financial results for the fourth quarter and full year of 2023.

Key Points: 
  • STAMFORD, Conn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported preliminary financial results for the fourth quarter and full year of 2023.
  • The preliminary, unaudited results presented in this press release for the year ended December 31, 2023, are based on current expectations and are subject to adjustment, as the company completes the preparation of its 2023 year-end consolidated financial statements and its 2023 year-end audit.
  • GeneDx will release financial results for the fourth quarter and full year of 2023 after the market closes on Tuesday, February 20, 2024.
  • On the same day, Katherine Stueland, President and Chief Executive Officer of GeneDx, and Kevin Feeley, Chief Financial Officer of GeneDx, will host a conference call to discuss financial and operating results at 4:30 p.m. Eastern Time.